



Curriculum Vitae

Personal information **María Isabel Lucena**

Work experience

1. Employer: University of Malaga
 - Start date: 2008
 - End date:
 - Position: Full Professor of Pharmacology. Head of the Pharmacology & Paediatrics Department. School of Medicine. University of Malaga.
 - Activities:
 - Country: Spain
2. Employer: Malaga University Hospital
 - Start date: 2007
 - End date:
 - Position: Director of the Unit of Clinical Pharmacology Service. Malaga University Hospital (Spain).
 - Activities:
 - Country: Spain
3. Employer: ISCIII
 - Start date: 2014
 - End date:
 - Position: Coordinating the Platform for Clinical Studies and Clinical Trials, Ministry of Health, ISCIII
 - Activities:
 - Country: Spain

Education and training

1. Subject: School of Medicine. University of Malaga.
 - Start date:
 - End date: 1980
 - Qualification: M.D. degree with full honours cum Laude.
 - Organisation:
 - Country: Spain
2. Subject: School of Medicine. University of Granada
 - Start date:
 - End date: 1983
 - Qualification: Assistant Professor of Pharmacology.
 - Organisation:
 - Country: Spain
3. Subject: University of Granada. School of Medicine.
 - Start date:
 - End date: 1984
 - Qualification: PhD degree in Medicine. Outstanding cum Laude. Premium Extraordinary.
 - Organisation:
 - Country: Spain
4. Subject: Certificate (specialist) in Clinical Pharmacology
 - Start date:
 - End date: 1984
 - Qualification: Certificate (specialist) in Clinical Pharmacology
 - Organisation:
 - Country: Spain

Additional information

Publications

THE MOST IMPORTANT PUBLICATIONS OF THE LAST 5 YEARS D1 SENIOR:

Di Zeo D, Irene Díaz-Alberola, José María Pinazo-Bandera, Miren García-Cortés, Judith Sanabria-Cabrera, Mercedes Robles-Díaz, Ismael Álvarez-Álvarez, **Lucena MI**, Andrade Rj, Villanueva-Paz M, Stephens C. Intestinal permeability and immune-inflammatory markers in patients with idiosyncratic drug-induced liver injury, drug-induced steatosis and metabolic dysfunction-associated steatotic liver disease (MASLD). Br J Pharmacol **2025**; 1-14. FI 2024: 7.7 (D1: 18/352) PHARMACOLOGY & PHARMACY. PMID: 40562415. DOI: 10.1111/bph.70123. **CORRESPONDING AUTHOR**

Bessone F, Hernandez N, Medina-Caliz I, García-Cortés M, Schinoni Mi, Mendizabal M, Chiodi D, Nunes V, Ridruejo E, Pazos X, Santos G, Fassio E, Parana R, Reggiardo V, Tanno H, Sanchez A, Tanno F, Montes P, Tagle M, Arrese M, Brahm J, Giral M, Lizarabai Mi, Carrera E, Zerega A, Bianchi C, Reyes L, Arnedillo D, Cordone A, Gualano G, Jaureguizar F, Rifrani G, Robles-Díaz M, Ortega-Alonso A, Pinazo-Bandera Jm, Stephens C, Sanabria-Cabrera J, Bonilla-Toyos E, Niu H, Alvarez-Alvarez I, **Lucena MI**, Andrade RJ. Drug-Induced Liver Injury in Latin America: 10-year experience of the Latin American DILI (LATINDILI) Network Drug-induced liver injury in Latin America. Clin Gastroenterol Hepatol. **2025**; 23(1):89-102. FI 2024: 12 (D1: 9/147) GASTROENTEROLOGY & HEPATOLOGY. doi: 10.1016/j.cgh.2024.06.030. PMID: 38992407. **SENIOR, CORRESPONDING AUTHOR**

Antonio Segovia-Zafra, Marina Villanueva-Paz, Ana Sofia Serras, Gonzalo Matilla-Cabello, Ana Bodoque-García,

Daniel Di Zeo-Sánchez, Hao Niu, Ismael Álvarez-Álvarez, Laura Sanz-Villanueva, Sergej Godec, Irina Milisav, Pierre Bagnaninchi, Raúl J. Andrade, **M Isabel Lucena**, José C. Fernández-Checa, Francisco Javier Cubero, Joana P. Miranda, Leonard J. Nelson. Control Compounds for Preclinical Drug-Induced Liver Injury Assessment: Consensus-driven systematic review by the ProEuroDILI Network. *Journal of Hepatology* **2024**; 81 (4): 630-640. FI 2024: 33 (D1: 3/147) **CORRESPONDING AUTHOR**. PMID: 38703829. <https://doi.org/10.1016/j.jhep.2024.04.026>

Niu H, Ma J, Medina-Caliz I, Robles-Diaz M, Bonilla-Toyos E, Ghabril M, **Lucena MI**, Alvarez-Alvarez I, Andrade RJ. Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis. *Aliment Pharmacol Ther.* 2023; 57(8):886-896. doi: 10.1111/apt.17373. PMID: 36547393. FI 2024: 6.7 (D1: 26/352) **CORRESPONDING AUTHOR**

Hayashi PH, **Lucena MI**, Fontana RJ, Bjornsson ES, Aithal GP, Barnhart H, Gonzalez-Jimenez A, Yang Q, Gu J, Andrade RJ, Hoofnagle JH. A revised electronic version of RUCAM for the diagnosis of DILI. *Hepatology.* 2022;76(1):18-31. doi: 10.1002/hep.32327. PMID: 35014066. FI 2024: 15.8, **D1** (7/147) **CO-FIRST AUTHOR**

Rodriguez-Diaz C, Taminiau B, García-García A, Cueto A, Robles-Díaz M, Ortega-Alonso A, Martín-Reyes F, Daube G, Sanabria-Cabrera J, Jimenez-Perez M, Isabel **Lucena M**, Andrade RJ, García-Fuentes E, García-Cortes M. Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. *Pharmacol Res.* 2022; 182:106348. doi: 10.1016/j.phrs.2022.106348. PMID: 35817360. FI 2024: 10.5 (D1: 13/352) **CORRESPONDING AUTHOR**

Niu H, Sanabria-Cabrera J, Alvarez-Alvarez I, Robles-Diaz M, Stankevičiūtė S, Aithal GP, Björnsson ES, Andrade RJ, **Lucena MI**. Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. *Pharmacol Res.* 2021; 164:105404. doi: 10.1016/j.phrs.2020.105404. PMID: 33359912. **FI 2024: 10.5** (D1: 13/352) **CORRESPONDING AUTHOR**

Stephens C, Robles-Diaz M, Medina-Caliz I, García-Cortes M, Ortega-Alonso A, Sanabria-Cabrera J, Gonzalez-Jimenez A, Alvarez-Alvarez I, Slim M, Jimenez-Perez M, Gonzalez-Grande R, Fernández MC, Casado M, Soriano G, Román E, Hallal H, Romero-Gomez M, Castiella A, Conde I, Prieto M, Moreno-Planas JM, Giraldez A, Moreno-Sanfiel JM, Kaplowitz N, **Lucena MI**, Andrade RJ; Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. *J Hepatol.* 2021 Jul;75(1):86-97. doi: 10.1016/j.jhep.2021.01.029. PMID: 33539847. FI 2024: 33 (D1: 3/147) **CORRESPONDING AUTHOR**

Bessone F, García-Cortés M, Medina-Caliz I, Hernandez N, Parana R, Mendizabal M, Schinoni MI, Ridruejo E, Nunes V, Peralta M, Santos G, Anders M, Chiodi D, Tagle M, Montes P, Carrera E, Arrese M, Lizarzabal MI, Alvarez-Alvarez I, Caballano-Infantes E, Niu H, Pinazo J, Cabello MR, **Lucena MI**, Andrade RJ. Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. *Clin Gastroenterol Hepatol.* 2022;20(3):e548-e563. doi: 10.1016/j.cgh.2021.01.011. PMID: 33434654. FI 2024: 12 (D1: 9/147) **SENIOR AND CORRESPONDING AUTHOR**

Cueto-Sanchez A, Niu H, Del Campo-Herrera E, Robles-Díaz M, Sanabria-Cabrera J, Ortega-Alonso A, García-Cortes M, Gonzalez-Grande R, Jimenez-Perez M, Ruiz-Cabello F, Andrade RJ, **Lucena MI**, Stephens C. Lymphocyte Profile and Immune Checkpoint Expression in Drug-Induced Liver Injury: An Immunophenotyping Study. *Clin Pharmacol Ther.* 2021;110(6):1604-1612. doi: 10.1002/cpt.2423. PMID: 34543448. FI 2024: 5.5, **D1** (34/352) **CO-ULTIMO AUTHOR (SENIOR)**

Projects

RESEARCH SUPPORT:

Participates and coordinates several international initiatives: Scientific Coordinator of the COST Action CA-7112 Pro Euro DILI NET (Prospective European Drug-Induced Liver Injury Network) (2018-2023). International collaborations: partners in the IMI Safer and Faster Evidence Based Translation consortium (SAFE-T, 2008-2015), the International Serious Adverse Event Consortium (ISAEC), IMI2 TRANSBIOLINE project (2019-2025), Eurostars Programme: Novel Combo Assay for Early Detection of DILI (E!114589-LiverAce. 2021-2023) and HALT-RONIN-Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies.PI WP5 HORIZON-HLTH-2022-STAYHLTH-02 (2022-2026); FDA project: Identify genetic and nongenetic factors associated with increased susceptibility to herbal dietary supplement (HDS)-induced liver injury in women.

Collaborations: Prof Kaplowitz (Universidad del Sur de California), Suzuki A. (Universidad de Duke), Aithal GP (Universidad de Nottingham), Prof E Bjornsson (Universidad de Islandia) y M Chen (National Center for Toxicological Research-FDA). This work has allowed a leading position in international DILI research.

Memberships

- European Association for the Study of Liver Diseases
- The European Association for Clinical Pharmacology and Therapeutics (EACPT)
- Member of the Executive Committee of the International Union of Basic and Clinical Pharmacology IUPHAR.
- Member of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) of the European Medicines Agency (EMA)
- Member of the European Clinical Research Infrastructures Network (ECRIN).
- International Serious Adverse Event Consortium.
- International Consortium on Drug Hypersensitivity (IDILIC) ("Network") □ SAFE_T Consortium (Safer and Faster Evidence_based Translation) of the European Union's Innovative Medicines Initiative (http://www.imi_safe_t.eu/) □ Advisory Board CRO InPEC

Other Relevant Information

She has received continuous competitive funding. She published over 20 book chapters and more than 250 articles in peer-review journals. She has an H-index of 56 and 11773 citations. 9th among the world experts in 'Chemical and Drug-Induced Liver Injury'(expertscape.com). The Instituto de Salud Carlos III leads the ranking in the area of Liver Toxicity worldwide. Position 234 in the ranking of Spanish and foreign female researchers in Spain (webometrics.info/en/investigadoras). She has directed 27 PhD thesis included 4 International thesis, 5 Extraordinary awards and 1 doctoral thesis co-tutelle with the University of Maastricht (2021). Human resources obtained through competitive convocatories: 3 technicians Garantía Juvenil (2016-2022), 3 Rio Hortega contracts (2017,2019,2023), 1 Sara Borrell (2021), 3 contracts for the Platform of Clinical research and clinical trials, 1 industrial i-PFIS IFI18/00047, 1 Phd Contract (2022) (POSTDOC_21_00780) , 1 Juan Rodés Contract JR21/00066 (2021), 1 CIBERehd Jaume Bosh Contract (2022), 1 Investigo Programme Contract (2023). Predoctoral PREP2022-000511 (MINECO 2024). 1 postdoc con el Proyecto CERTERA (CERT22/00034)